This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kyttaris, V C Articles by Tsokos, G C Search for Related Content PubMed PubMed Citation Articles by Kyttaris, V C Articles by Tsokos, G C Social Bookmarking                   What's this?

Gene therapy in systemic lupus erythematosus

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA, Division of Rheumatology, Washington Hospital Center, Washington, DC, USA

Y-T Juang

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA

G C Tsokos

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA, gtsokos{at}usa.net

Preclinical studies have provided proof of concept for the feasibility and efficacy of gene therapy in human systemic lupus erythematosus (SLE). Successful efforts include gene constructs that alter the expression of cytokines or limit the cognate interaction of immune cells. Other efforts may include gene modified cell transfersuch as autologousB cells transfectedwith tolerogenicconstructsor T cells in which specific molecular aberrations have been corrected.

Key Words: all therapy • cytokines • gene therapy • genetics • SLE

Lupus, Vol. 13, No. 5, 353-358 (2004)
DOI: 10.1191/0961203304lu1026oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S Vasoo and G R. Hughes Theory, targets and therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 181 - 188. [Abstract] [PDF]